{"transactions":[{"id":711131,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-10T16:15:14.000Z","date":"2026-07-08","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026."}],"balance_after":6500,"derivative":{"exercise_price":7.14,"expiration_date":"2036-07-07","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001193125-26-300927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1406337/000119312526300927/ownership.xml","form_type":"4"}},{"id":1173244,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T16:05:12.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of April 10, 2026 or the day immediately prior to the company's 2026 annual meeting of shareholders."}],"balance_after":100000,"derivative":{"exercise_price":0.58,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-25-053248","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1406337/000095017025053248/ownership.xml","form_type":"4"}},{"id":1459676,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-03T16:15:06.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":64564,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in four equal quarterly installments occurring on October 1, 2024, January 1, 2025, April 1, 2025 and July 1, 2025, provided that if the Company's 2025 annual meeting of stockholders occurs before July 1, 2025, the final quarterly vesting installment will vest on the day immediately prior to the date of such annual meeting, in each case, subject to the reporting person continuing in service on the Board as a non-employee director through the applicable vesting date."}],"balance_after":64564,"derivative":{"exercise_price":0.72,"expiration_date":"2034-06-30","underlying":"Common Stock","underlying_shares":64564},"source":{"system":"sec-edgar","filing":"0000950170-24-081522","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1406337/000095017024081522/ownership.xml","form_type":"4"}},{"id":1545380,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-08T16:45:19.000Z","date":"2024-04-04","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of April 4, 2025 or the day immediately prior to the company's 2025 annual meeting of shareholders."}],"balance_after":60000,"derivative":{"exercise_price":0.76,"expiration_date":"2034-04-03","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-24-042654","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1406337/000095017024042654/ownership.xml","form_type":"4"}},{"id":1845071,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T17:22:54.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 22, 2024 or the day immediately prior to the company's 2024 annual meeting of shareholders."}],"balance_after":35000,"derivative":{"exercise_price":5.46,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000899243-23-016397","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1406337/000089924323016397/doc4.xml","form_type":"4"}},{"id":2221930,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T16:35:31.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 22, 2023 or the day immediately prior to the company's 2023 annual meeting of shareholders."}],"balance_after":35000,"derivative":{"exercise_price":3.22,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000899243-22-024008","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1406337/000089924322024008/doc4.xml","form_type":"4"}},{"id":2221929,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T16:32:03.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 22, 2023 or the day immediately prior to the company's 2023 annual meeting of shareholders."}],"balance_after":35000,"derivative":{"exercise_price":3.22,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000899243-22-023989","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1406337/000089924322023989/doc4.xml","form_type":"4"}},{"id":2660720,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-21T16:30:40.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 16, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders."}],"balance_after":23000,"derivative":{"exercise_price":19.74,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0000899243-21-024995","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1406337/000089924321024995/doc4.xml","form_type":"4"}},{"id":3103013,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-22T16:12:39.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 18, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders."}],"balance_after":30000,"derivative":{"exercise_price":4.4,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-20-017356","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1406337/000089924320017356/doc4.xml","form_type":"4"}},{"id":3252765,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-24T17:54:59.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on February 20, 2021, subject to continued service with RDUS through such date."}],"balance_after":10000,"derivative":{"exercise_price":19.96,"expiration_date":"2030-02-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-012146","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919120012146/doc4.xml","form_type":"4"}},{"id":3252764,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-24T17:54:59.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":5500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on February 20, 2021, subject to continued service with RDUS through such date."}],"balance_after":11000,"source":{"system":"sec-edgar","filing":"0001209191-20-012146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919120012146/doc4.xml","form_type":"4"}},{"id":3299072,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:14:23.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":42000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":2.18,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001562180-20-000672","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000672/primarydocument.xml","form_type":"4"}},{"id":3299071,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:14:23.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":2.9,"expiration_date":"2028-02-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001562180-20-000672","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000672/primarydocument.xml","form_type":"4"}},{"id":3299070,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:14:23.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":3.02,"expiration_date":"2023-12-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-20-000672","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000672/primarydocument.xml","form_type":"4"}},{"id":3299069,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:14:23.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":4.09,"expiration_date":"2027-01-19","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001562180-20-000672","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000672/primarydocument.xml","form_type":"4"}},{"id":3299068,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:14:23.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":135000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":6.12,"expiration_date":"2022-06-11","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001562180-20-000672","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000672/primarydocument.xml","form_type":"4"}},{"id":3299067,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:14:23.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."}],"balance_after":0,"derivative":{"exercise_price":7.54,"expiration_date":"2026-01-25","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001562180-20-000672","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000672/primarydocument.xml","form_type":"4"}},{"id":3299066,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-29T16:14:23.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":22709,"price":6.3,"value":143066.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the merger agreement (the \"Merger Agreement\") among Achillion Pharmaceuticals, Inc. (\"Achillion\"), Alexion Pharmaceuticals, Inc. (\"Alexion\") and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right (\"CVR\") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-20-000672","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000672/primarydocument.xml","form_type":"4"}},{"id":3489435,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-14T16:11:08.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 13, 2020 or the day immediately prior to the company's 2020 annual meeting of shareholders."}],"balance_after":15000,"derivative":{"exercise_price":2.83,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-19-017016","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1406337/000089924319017016/doc4.xml","form_type":"4"}},{"id":3553149,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-18T16:44:11.000Z","date":"2019-04-16","kind":"sale","acquired":false,"shares":4800,"price":22.32,"value":107136.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.03 to $22.54, inclusive. The reporting person undertakes to provide to Radius Health, Inc., any security holder of Radius Health, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":5500,"source":{"system":"sec-edgar","filing":"0001209191-19-025252","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919119025252/doc4.xml","form_type":"4"}},{"id":3631891,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-26T18:14:03.000Z","date":"2019-02-22","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on February 22, 2020, subject to continued service with RDUS through such date."}],"balance_after":10000,"derivative":{"exercise_price":19.18,"expiration_date":"2029-02-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-013704","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919119013704/doc4.xml","form_type":"4"}},{"id":3631890,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-26T18:14:03.000Z","date":"2019-02-22","kind":"grant","acquired":true,"shares":5500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on February 22, 2020, subject to continued service with RDUS through such date."}],"balance_after":10300,"source":{"system":"sec-edgar","filing":"0001209191-19-013704","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919119013704/doc4.xml","form_type":"4"}},{"id":3660242,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-02-13T17:21:26.000Z","date":"2019-02-13","kind":"exercise","acquired":false,"shares":4800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of RDUS common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vested in full on February 13, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vested in full on February 13, 2019."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4800},"source":{"system":"sec-edgar","filing":"0001209191-19-009745","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919119009745/doc4.xml","form_type":"4"}},{"id":3660241,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-13T17:21:26.000Z","date":"2019-02-13","kind":"exercise","acquired":true,"shares":4800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of RDUS common stock."}],"balance_after":4800,"source":{"system":"sec-edgar","filing":"0001209191-19-009745","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919119009745/doc4.xml","form_type":"4"}},{"id":3686967,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2019-01-25T16:52:51.000Z","date":"2019-01-23","kind":"grant","acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable in equal quarterly installments over the one-year period following the date of grant."}],"balance_after":42000,"derivative":{"exercise_price":2.18,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001209191-19-005378","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000120919119005378/doc4.xml","form_type":"4"}},{"id":3882177,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-27T21:01:59.000Z","date":"2018-06-26","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 26, 2019 or the day immediately prior to the company's 2019 annual meeting of shareholders."}],"balance_after":15000,"derivative":{"exercise_price":9.09,"expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-18-018511","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1406337/000089924318018511/doc4.xml","form_type":"4"}},{"id":4054643,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-02-15T19:40:24.000Z","date":"2018-02-13","kind":"grant","acquired":true,"shares":4800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of RDUS common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units shall vest in full on February 13, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units shall vest in full on February 13, 2019."}],"balance_after":4800,"derivative":{"underlying":"Common Stock","underlying_shares":4800},"source":{"system":"sec-edgar","filing":"0001209191-18-010548","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919118010548/doc4.xml","form_type":"4"}},{"id":4054642,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-15T19:40:24.000Z","date":"2018-02-13","kind":"grant","acquired":true,"shares":8800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on February 13, 2019, subject to continued service to the Issuer through such date."}],"balance_after":8800,"derivative":{"exercise_price":37.83,"expiration_date":"2028-02-12","underlying":"Common Stock","underlying_shares":8800},"source":{"system":"sec-edgar","filing":"0001209191-18-010548","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919118010548/doc4.xml","form_type":"4"}},{"id":4063627,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option","published_at":"2018-02-13T17:18:25.000Z","date":"2018-02-09","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 25% of the original number of shares on the date of grant and as to an additional 2.08% of the original number of shares at the end of each monthly period thereafter."}],"balance_after":30000,"derivative":{"exercise_price":2.9,"expiration_date":"2028-02-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-18-009661","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000120919118009661/doc4.xml","form_type":"4"}},{"id":4275215,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-21T17:15:22.000Z","date":"2017-06-20","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of June 20, 2018 or the day immediately prior to the company's 2018 annual meeting of shareholders."}],"balance_after":15000,"derivative":{"exercise_price":11.21,"expiration_date":"2027-06-19","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-17-016860","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1406337/000089924317016860/doc4.xml","form_type":"4"}},{"id":4431346,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-22T16:26:24.000Z","date":"2017-02-17","kind":"grant","acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on February 17, 2018, subject to continued service to the Issuer through such date."}],"balance_after":27500,"derivative":{"exercise_price":45.65,"expiration_date":"2027-02-16","underlying":"Common Stock","underlying_shares":27500},"source":{"system":"sec-edgar","filing":"0001209191-17-013253","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919117013253/doc4.xml","form_type":"4"}},{"id":4486924,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option","published_at":"2017-01-19T17:25:34.000Z","date":"2017-01-19","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 25% of the original number of shares on the date of grant and as to an additional 2.08% of the original number of shares at the end of each monthly period thereafter."}],"balance_after":30000,"derivative":{"exercise_price":4.09,"expiration_date":"2027-01-19","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-17-004616","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000120919117004616/doc4.xml","form_type":"4"}},{"id":527516,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,  Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2009-10-21T17:55:30.000Z","date":"2009-10-19","kind":"sale","acquired":false,"shares":1500,"price":34.7,"value":52050.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $34.70 (range $34.56 to $34.83)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Graves undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":59880,"source":{"system":"sec-edgar","filing":"0000875320-09-000087","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532009000087/edgar.xml","form_type":"4"}},{"id":529421,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,  Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2009-07-21T20:48:49.000Z","date":"2009-07-20","kind":"sale","acquired":false,"shares":3868,"price":33.47,"value":129461.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $33.47 (range $33.26 to $33.73)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Graves undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":61380,"source":{"system":"sec-edgar","filing":"0000875320-09-000068","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532009000068/edgar.xml","form_type":"4"}},{"id":529426,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2009-07-20T19:31:46.000Z","date":"2009-07-16","kind":"grant","acquired":true,"shares":36250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/16/09."}],"balance_after":36250,"derivative":{"exercise_price":33.28,"exercise_date":"2009-10-16","expiration_date":"2019-07-15","underlying":"Common Stock","underlying_shares":36250},"source":{"system":"sec-edgar","filing":"0000875320-09-000065","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532009000065/edgar.xml","form_type":"4"}},{"id":530614,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,  Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2009-05-19T18:24:17.000Z","date":"2009-05-18","kind":"sale","acquired":false,"shares":925,"price":28.44,"value":26307.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $28.44 (range $28.12 to $28.93)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Graves undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":65248,"source":{"system":"sec-edgar","filing":"0000875320-09-000033","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532009000033/edgar.xml","form_type":"4"}},{"id":531293,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2009-04-29T20:00:02.000Z","date":"2009-04-28","kind":"sale","acquired":false,"shares":2507,"price":32,"value":80224.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1."}],"balance_after":65248,"source":{"system":"sec-edgar","filing":"0000875320-09-000022","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532009000022/edgar.xml","form_type":"4"}},{"id":531410,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2009-04-22T19:01:27.000Z","date":"2009-04-21","kind":"sale","acquired":false,"shares":210,"price":27.34,"value":5741.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $27.34 (range $27.19 to $27.65)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Mr. Graves undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":67755,"source":{"system":"sec-edgar","filing":"0000875320-09-000021","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532009000021/edgar.xml","form_type":"4"}},{"id":531409,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2009-04-22T19:01:27.000Z","date":"2009-04-21","kind":"sale","acquired":false,"shares":283,"price":26.72,"value":7561.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a wieghted average price of $26.72 (range $26.51 to ($26.97)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Mr. Graves undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":67965,"source":{"system":"sec-edgar","filing":"0000875320-09-000021","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532009000021/edgar.xml","form_type":"4"}},{"id":533605,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2009-02-06T21:13:24.000Z","date":"2009-02-05","kind":"grant","acquired":true,"shares":54375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/09."}],"balance_after":54375,"derivative":{"exercise_price":33.55,"exercise_date":"2009-05-05","expiration_date":"2019-02-04","underlying":"Common Stock","underlying_shares":54375},"source":{"system":"sec-edgar","filing":"0000875320-09-000003","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532009000003/edgar.xml","form_type":"4"}},{"id":533604,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2009-02-06T21:13:24.000Z","date":"2009-02-05","kind":"grant","acquired":true,"shares":12084,"price":0.01,"value":120.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Stock grant made under 2006 Stock and Option Plan, vesting on 2/5/2013, subject to 50% acceleration upon filing a new drug application with the FDA for telaprevir and 50% acceleration upon the approval of a new drug application for telaprevir."}],"balance_after":68248,"source":{"system":"sec-edgar","filing":"0000875320-09-000003","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532009000003/edgar.xml","form_type":"4"}},{"id":535555,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-11-19T21:22:21.000Z","date":"2008-11-18","kind":"sale","acquired":false,"shares":379,"price":26.1,"value":9891.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a wieghted average price of $26.10 (range $25.75 to $26.53)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Graves undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":56164,"source":{"system":"sec-edgar","filing":"0000875320-08-000086","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000086/edgar.xml","form_type":"4"}},{"id":535996,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-10-22T18:32:01.000Z","date":"2008-10-21","kind":"sale","acquired":false,"shares":485,"price":25.65,"value":12440.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Graves' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $25.65 (range $25.27 to $25.97)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Graves undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":56164,"source":{"system":"sec-edgar","filing":"0000875320-08-000079","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000079/edgar.xml","form_type":"4"}},{"id":538687,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Options","published_at":"2008-07-25T15:14:22.000Z","date":"2008-07-24","kind":"grant","acquired":true,"shares":36250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/24/2008."}],"balance_after":36250,"derivative":{"exercise_price":32.16,"exercise_date":"2008-10-24","expiration_date":"2018-07-23","underlying":"Common Stock","underlying_shares":36250},"source":{"system":"sec-edgar","filing":"0000875320-08-000060","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000060/edgar.xml","form_type":"4"}},{"id":538772,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common  Stock","published_at":"2008-07-23T16:10:03.000Z","date":"2008-07-21","kind":"sale","acquired":false,"shares":2325,"price":32.71,"value":76050.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Graves' company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Open market sales reported on this line occurred at a weighted average price of $32.71 (range $32.54 to $32.94)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Mr. Graves undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."}],"balance_after":56649,"source":{"system":"sec-edgar","filing":"0000875320-08-000051","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000051/edgar.xml","form_type":"4"}},{"id":538771,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-07-23T16:10:03.000Z","date":"2008-07-21","kind":"sale","acquired":false,"shares":600,"price":31.89,"value":19134.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Graves' company approved trading plan under Rule 10b5-1."}],"balance_after":58974,"source":{"system":"sec-edgar","filing":"0000875320-08-000051","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000051/edgar.xml","form_type":"4"}},{"id":542897,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-06-09T16:30:36.000Z","date":"2008-06-05","kind":"sale","acquired":false,"shares":3549,"price":31.05,"value":110196.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Grave's company approved trading plan established under Rule 10b5-1."}],"balance_after":59574,"source":{"system":"sec-edgar","filing":"0000875320-08-000043","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000043/edgar.xml","form_type":"4"}},{"id":545632,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-05-22T13:30:37.000Z","date":"2008-05-20","kind":"sale","acquired":false,"shares":151,"price":27.69,"value":4181.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1."}],"balance_after":63123,"source":{"system":"sec-edgar","filing":"0000875320-08-000031","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000031/edgar.xml","form_type":"4"}},{"id":545631,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-05-22T13:30:37.000Z","date":"2008-05-20","kind":"sale","acquired":false,"shares":151,"price":27.67,"value":4178.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1."}],"balance_after":63274,"source":{"system":"sec-edgar","filing":"0000875320-08-000031","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000031/edgar.xml","form_type":"4"}},{"id":545630,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-05-22T13:30:37.000Z","date":"2008-05-20","kind":"sale","acquired":false,"shares":152,"price":27.47,"value":4175.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1."}],"balance_after":63425,"source":{"system":"sec-edgar","filing":"0000875320-08-000031","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000031/edgar.xml","form_type":"4"}},{"id":545629,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-05-22T13:30:37.000Z","date":"2008-05-20","kind":"sale","acquired":false,"shares":151,"price":27.46,"value":4146.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1."}],"balance_after":63577,"source":{"system":"sec-edgar","filing":"0000875320-08-000031","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000031/edgar.xml","form_type":"4"}},{"id":545628,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-05-22T13:30:37.000Z","date":"2008-05-20","kind":"sale","acquired":false,"shares":151,"price":27.74,"value":4188.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1."}],"balance_after":63728,"source":{"system":"sec-edgar","filing":"0000875320-08-000031","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000031/edgar.xml","form_type":"4"}},{"id":545627,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-05-22T13:30:37.000Z","date":"2008-05-20","kind":"sale","acquired":false,"shares":302,"price":27.61,"value":8338.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1."}],"balance_after":63879,"source":{"system":"sec-edgar","filing":"0000875320-08-000031","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000031/edgar.xml","form_type":"4"}},{"id":545626,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-05-22T13:30:37.000Z","date":"2008-05-20","kind":"sale","acquired":false,"shares":151,"price":27.59,"value":4166.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1."}],"balance_after":64181,"source":{"system":"sec-edgar","filing":"0000875320-08-000031","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000031/edgar.xml","form_type":"4"}},{"id":545625,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-05-22T13:30:37.000Z","date":"2008-05-20","kind":"sale","acquired":false,"shares":134,"price":27.58,"value":3695.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1."}],"balance_after":64332,"source":{"system":"sec-edgar","filing":"0000875320-08-000031","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000031/edgar.xml","form_type":"4"}},{"id":545624,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-05-22T13:30:37.000Z","date":"2008-05-20","kind":"sale","acquired":false,"shares":169,"price":27.5,"value":4647.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1."}],"balance_after":64466,"source":{"system":"sec-edgar","filing":"0000875320-08-000031","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000031/edgar.xml","form_type":"4"}},{"id":546971,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-05-15T19:16:52.000Z","date":"2008-05-13","kind":"sale","acquired":false,"shares":200,"price":27.63,"value":5526.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Grave's company approved trading plan established under Rule 10b5-1."}],"balance_after":63123,"source":{"system":"sec-edgar","filing":"0000875320-08-000025","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000025/edgar.xml","form_type":"4"}},{"id":546970,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-05-15T19:16:52.000Z","date":"2008-05-13","kind":"sale","acquired":false,"shares":200,"price":27.47,"value":5494.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Grave's company approved trading plan established under Rule 10b5-1."}],"balance_after":63323,"source":{"system":"sec-edgar","filing":"0000875320-08-000025","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000025/edgar.xml","form_type":"4"}},{"id":546969,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-05-15T19:16:52.000Z","date":"2008-05-13","kind":"sale","acquired":false,"shares":100,"price":27.38,"value":2738.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Grave's company approved trading plan established under Rule 10b5-1."}],"balance_after":63523,"source":{"system":"sec-edgar","filing":"0000875320-08-000025","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000025/edgar.xml","form_type":"4"}},{"id":546968,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-05-15T19:16:52.000Z","date":"2008-05-13","kind":"sale","acquired":false,"shares":100,"price":27.35,"value":2735.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Grave's company approved trading plan established under Rule 10b5-1."}],"balance_after":63623,"source":{"system":"sec-edgar","filing":"0000875320-08-000025","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000025/edgar.xml","form_type":"4"}},{"id":546967,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-05-15T19:16:52.000Z","date":"2008-05-13","kind":"sale","acquired":false,"shares":1,"price":27.12,"value":27.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Grave's company approved trading plan established under Rule 10b5-1."}],"balance_after":63723,"source":{"system":"sec-edgar","filing":"0000875320-08-000025","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000025/edgar.xml","form_type":"4"}},{"id":546966,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-05-15T19:16:52.000Z","date":"2008-05-13","kind":"sale","acquired":false,"shares":148,"price":27.09,"value":4009.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Grave's company approved trading plan established under Rule 10b5-1."}],"balance_after":63724,"source":{"system":"sec-edgar","filing":"0000875320-08-000025","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000025/edgar.xml","form_type":"4"}},{"id":546965,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-05-15T19:16:52.000Z","date":"2008-05-13","kind":"sale","acquired":false,"shares":2,"price":27.07,"value":54.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Grave's company approved trading plan established under Rule 10b5-1."}],"balance_after":63872,"source":{"system":"sec-edgar","filing":"0000875320-08-000025","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000025/edgar.xml","form_type":"4"}},{"id":546964,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-05-15T19:16:52.000Z","date":"2008-05-13","kind":"sale","acquired":false,"shares":200,"price":27,"value":5400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Mr. Grave's company approved trading plan established under Rule 10b5-1."}],"balance_after":63874,"source":{"system":"sec-edgar","filing":"0000875320-08-000025","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000025/edgar.xml","form_type":"4"}},{"id":559411,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2008-02-11T20:58:52.000Z","date":"2008-02-07","kind":"grant","acquired":true,"shares":90625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from 02/07/2008, subject to shareholder approval."}],"balance_after":90625,"derivative":{"exercise_price":18.93,"exercise_date":"2008-05-07","expiration_date":"2018-02-06","underlying":"Common Stock","underlying_shares":90625},"source":{"system":"sec-edgar","filing":"0000875320-08-000011","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000011/edgar.xml","form_type":"4"}},{"id":559410,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2008-02-11T20:58:52.000Z","date":"2008-02-07","kind":"grant","acquired":true,"shares":12084,"price":0.01,"value":120.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Stock grant made under 2006 Stock and Option Plan, vesting on 2/7/2012, subject to acceleration upon achievement of certain performance-based milestones."}],"balance_after":64074,"source":{"system":"sec-edgar","filing":"0000875320-08-000011","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532008000011/edgar.xml","form_type":"4"}},{"id":565275,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2007-11-07T21:19:13.000Z","date":"2007-11-06","kind":"purchase","acquired":true,"shares":790,"price":25.25,"value":19947.5,"ownership":{"direct":true},"balance_after":51990,"source":{"system":"sec-edgar","filing":"0000875320-07-000104","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532007000104/edgar.xml","form_type":"4"}},{"id":565274,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2007-11-07T21:19:13.000Z","date":"2007-11-06","kind":"purchase","acquired":true,"shares":1308,"price":25.14,"value":32883.12,"ownership":{"direct":true},"balance_after":51200,"source":{"system":"sec-edgar","filing":"0000875320-07-000104","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532007000104/edgar.xml","form_type":"4"}},{"id":565273,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2007-11-07T21:19:13.000Z","date":"2007-11-06","kind":"purchase","acquired":true,"shares":300,"price":25.15,"value":7545.0,"ownership":{"direct":true},"balance_after":49892,"source":{"system":"sec-edgar","filing":"0000875320-07-000104","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532007000104/edgar.xml","form_type":"4"}},{"id":565272,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2007-11-07T21:19:13.000Z","date":"2007-11-06","kind":"purchase","acquired":true,"shares":100,"price":25.12,"value":2512.0,"ownership":{"direct":true},"balance_after":49592,"source":{"system":"sec-edgar","filing":"0000875320-07-000104","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532007000104/edgar.xml","form_type":"4"}},{"id":565271,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2007-11-07T21:19:13.000Z","date":"2007-11-06","kind":"purchase","acquired":true,"shares":1000,"price":25.11,"value":25110.0,"ownership":{"direct":true},"balance_after":49492,"source":{"system":"sec-edgar","filing":"0000875320-07-000104","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532007000104/edgar.xml","form_type":"4"}},{"id":565270,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2007-11-07T21:19:13.000Z","date":"2007-11-06","kind":"purchase","acquired":true,"shares":100,"price":25.1,"value":2510.0,"ownership":{"direct":true},"balance_after":48492,"source":{"system":"sec-edgar","filing":"0000875320-07-000104","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532007000104/edgar.xml","form_type":"4"}},{"id":565269,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2007-11-07T21:19:13.000Z","date":"2007-11-06","kind":"purchase","acquired":true,"shares":392,"price":25.09,"value":9835.28,"ownership":{"direct":true},"balance_after":48392,"source":{"system":"sec-edgar","filing":"0000875320-07-000104","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532007000104/edgar.xml","form_type":"4"}},{"id":575277,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option","published_at":"2007-07-18T17:30:20.000Z","date":"2007-07-17","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments over four years."}],"balance_after":100000,"derivative":{"exercise_price":28.85,"exercise_date":"2007-10-17","expiration_date":"2017-07-16","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000875320-07-000082","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532007000082/edgar.xml","form_type":"4"}},{"id":575276,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2007-07-18T17:30:20.000Z","date":"2007-07-17","kind":"grant","acquired":true,"shares":18000,"price":0.01,"value":180.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Stock grant made under 2006 Stock and Option Plan vesting in 12 equal quarterly installments over three years."}],"balance_after":48000,"source":{"system":"sec-edgar","filing":"0000875320-07-000082","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532007000082/edgar.xml","form_type":"4"}},{"id":575275,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":17029,"kind":"person","name":"Graves Kurt","position":1,"cik":"0001406337","reported_name":"Graves Kurt","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2007-07-18T17:30:20.000Z","date":"2007-07-17","kind":"grant","acquired":true,"shares":30000,"price":0.01,"value":300.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Stock grant made under 2006 Stock and Option Plan vesting in four equal annual installments over four years."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0000875320-07-000082","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532007000082/edgar.xml","form_type":"4"}}]}